抄録
The American College of Cardiology’s (ACC) 62nd Annual Scientific Session was held at the Moscone Center, San Francisco, from March 9–11, 2013. The meeting focused on the “transformation of cardiovascular care, from discovery to delivery”, featured over 20 late-breaking clinical trials and 2,000 abstracts. These sessions gave notable exposure and recognition of studies likely to significantly affect clinical practice. There were 21 trials scheduled for presentation in 5 featured Late-Breaking Clinical Trial sessions, but one, the PREVAIL trial, was not presented because of a failure to observe an embargo. I summarize and overview both the late-breaking trials presented at ACC 2013 and the PREVAIL trial.
